Project Consultancy, Reports & Profiles

Few manufacturing business opportunities in India combine the scale of global trade with the depth of domestic demand the way Active Pharmaceutical Ingredient production does. APIs — the chemically active compounds that give every medicine its therapeutic effect — sit at the foundation of the entire pharmaceutical supply chain. Without them, no finished drug reaches a patient.

India today manufactures APIs for roughly 500 different drug substances and exports them to over 200 countries. For any entrepreneur exploring high-value business ideas in industrial chemistry or life sciences, the API sector offers a combination that is hard to replicate: proven export markets, government policy support, and a structural tailwind as countries worldwide reduce dependence on single-source supply chains.

This guide covers market size, investment requirements, government incentives, major players, and the realistic growth trajectory of bulk API manufacturing in India through 2035.

Why API Manufacturing Is a Strategic Business Choice Right Now

The COVID-19 pandemic exposed a fragile reality: much of the world — including India — was dangerously dependent on Chinese imports for key API raw materials. That wake-up call triggered policy action across the US, Europe, and India simultaneously. The result is a historic realignment of pharmaceutical supply chains, and India is positioned to capture the largest share of that shift.

China supplies an estimated 70–80% of India's fermentation-based API requirements (Ministry of Chemicals and Fertilizers data). Reducing that dependency is now a stated national priority, backed by real funding. For new entrants, this creates an unusual opening: government subsidies, preferential procurement, and new export markets — all converging at once.

India exported pharmaceutical products worth approximately USD 27.8 billion in 2023–24 — with bulk drugs and APIs accounting for a significant share, according to Pharmexcil data.

Beyond geopolitics, India's domestic pharma market is itself expanding rapidly. Rising chronic disease burden, improved insurance coverage under Ayushman Bharat, and an aging population are collectively pushing formulation manufacturers to secure more reliable API supply. That creates steady domestic offtake even before exports are considered.

Market Demand & Statistics: Who Buys APIs and Why

Which Industries Drive API Consumption?

The primary buyer of APIs is the formulations industry — manufacturers of tablets, capsules, injectables, and syrups. India has over 10,500 licensed pharmaceutical manufacturing units (Ministry of Health & Family Welfare estimates), each dependent on API supply. Beyond finished-drug makers, contract research and manufacturing organisations (CRAMOs) and veterinary medicine producers are growing consumption segments.

Globally, therapeutic segments driving the highest API demand include cardiovascular drugs, oncology compounds, anti-diabetics, antibiotics, and anti-retrovirals. India is already a significant global supplier in antibiotics (penicillin derivatives, cephalosporins), anti-malarials, and anti-retrovirals. Oncology APIs — historically an import-heavy category — are an emerging domestic manufacturing opportunity.

Demand for specialty API manufacturing is also rising sharply, driven by biosimilars and complex generics. These higher-value segments require advanced synthesis capabilities but command significantly better margins than commodity APIs.

Government Policies, Incentives & Facilities for API Producers

The central government has launched several targeted interventions for the pharmaceutical API industry. The Production Linked Incentive (PLI) Scheme for Bulk Drugs — with an approved outlay of ₹6,940 crore — directly incentivises domestic production of 41 identified KSMs/APIs that India currently imports in large volumes. Eligible companies receive a 10–20% incentive on incremental sales for six years.

Alongside the PLI scheme, three dedicated Bulk Drug Parks are being developed in Himachal Pradesh, Andhra Pradesh, and Gujarat under the Bulk Drug Parks Promotion Scheme, with central funding up to ₹1,000 crore per park. These parks provide ready plug-and-play infrastructure — common effluent treatment, solvent recovery, and warehousing — significantly lowering entry barriers.

For MSMEs, the CGTMSE scheme provides collateral-free credit guarantees up to ₹2 crore, while the CLCSS scheme supports technology upgradation with a 15% capital subsidy. The RoDTEP scheme covers export duty and levies, supporting API exporters' price competitiveness in global tenders.

At the state level, Telangana's TS-iPASS single-window system and Andhra Pradesh's industrial incentive framework offer land allotment, power tariff concessions, and VAT refunds for pharmaceutical manufacturers. Himachal Pradesh and Uttarakhand continue to offer legacy excise and income-tax exemptions for pharma units set up in notified areas.

Is the PLI Scheme Actually Beneficial for Small API Manufacturers?

The PLI Scheme is designed primarily for medium-to-large players producing identified KSMs and APIs. Smaller manufacturers benefit more from the MSME schemes, Bulk Drug Park infrastructure, and state-level subsidies. However, small units supplying to PLI-eligible large manufacturers can benefit indirectly through volume offtake agreements.

Market Growth & Industry Outlook

India's API manufacturing industry has grown consistently over the last decade. Pharmexcil estimates place India's bulk drug exports at around USD 5.4 billion in 2022–23, up from approximately USD 3.2 billion five years earlier. The domestic API market, serving India's formulation sector, adds another significant layer of demand.

Several structural factors sustain the growth trajectory: the global generic drug market is expanding as branded drug patents expire in the US and Europe; biosimilar APIs are a new high-value opportunity; and "China+1" sourcing strategies by global pharma companies actively redirect procurement toward India.

Entry into fermentation-based APIs (antibiotics, immunosuppressants) requires significant capital and regulatory clearance, but commands premium pricing and high barriers to entry for late competitors. For entrepreneurs with access to sufficient capital and technical expertise, this segment offers durable margins. Smaller players may find better initial traction in semi-synthetic APIs or intermediates that feed the larger API manufacturers.

Year-Wise Market Data: India API Sector

Note: Forecast figures from 2027 onward are projections based on an assumed CAGR of 10–12% and are not confirmed market research figures.

Market Forecast to 2035: The Long View

By 2035, India's API manufacturing sector could realistically reach USD 18–20 billion in annual production value, based on an assumed 10–12% CAGR from the 2023–24 base (this is an industry estimate, not confirmed research data). The primary growth levers are: increased generic drug consumption in regulated markets (US, EU, Canada, Australia); rising biosimilar API production; and government-backed import substitution of over 40 critical KSMs.

The US FDA-approved Indian API plants — currently numbering over 500 (Ministry of Chemicals estimates) — give Indian manufacturers a regulatory head-start that new entrants from other countries would take years to replicate. This regulatory moat is itself a significant competitive advantage for existing and new Indian API producers seeking export-market entry.

India accounts for roughly 20% of global generic drug exports by volume — a position that is structurally dependent on a robust domestic API manufacturing base, according to industry association data.

Import–Export Opportunity Analysis

How Does India Balance API Trade?

India simultaneously imports and exports APIs, but in different categories. The country is a net exporter in antibiotics, anti-malarials, and anti-retrovirals, while being a net importer in fermentation-based intermediates, oncology APIs, and certain specialty compounds — largely from China.

DGFT and Pharmexcil data show that India's pharmaceutical export base is growing in regulated markets. The US remains the single largest export destination, absorbing close to 30% of India's pharmaceutical exports. Europe (primarily Germany, UK, Netherlands) and emerging markets in Africa and Latin America are the other significant destinations.

The import side presents an entrepreneurial opportunity: any API currently imported from China in large volumes is a priority target for domestic manufacturing under the PLI scheme. DPIIT tracks the import substitution pipeline; entrepreneurs can identify high-volume imports and assess feasibility against PLI incentives.

Major Indian API Manufacturers

Future Growth Potential & Reasons to Enter This Sector

Three converging forces make the next five to ten years an unusually favourable window for new entrants into bulk drug manufacturing. First, China+1 diversification is not a trend but a procurement policy across major US and European pharma buyers — and it is creating real, durable demand for Indian API suppliers. Second, the PLI scheme and Bulk Drug Parks directly de-risk capital investment for qualifying manufacturers. Third, India's regulatory standing with the US FDA and European EMA is hard-won and difficult for competitors to replicate quickly.

Biosimilar APIs and complex molecule synthesis are the highest-growth segments looking toward 2035. Both require deep chemistry expertise and regulatory investment, but both also command margins that commodity API manufacturers cannot achieve. For entrepreneurs with scientific backgrounds or access to qualified chemistry talent, these segments offer disproportionate long-term returns.

Cost & Investment Data: API Manufacturing Plant

Note: These are indicative industry estimates. Actual costs depend on product complexity, geography, and regulatory target markets.

Frequently Asked Questions

Is API manufacturing profitable in India?

Yes — API manufacturing profitability in India varies by segment. Commodity APIs (paracetamol, metformin) operate on thin margins of 8–12%, while specialty and complex APIs can yield 25–40% EBITDA margins. Export-focused units benefiting from PLI incentives can further enhance returns. Profitability depends heavily on product selection, scale, and regulatory compliance status.

What licences are needed to start an API manufacturing plant in India?

To start an API manufacturing unit in India, you need a Drug Manufacturing Licence from the State Drug Controller (Form 25-D under the Drugs and Cosmetics Act), factory registration, pollution control clearances (NOC from State PCB), GST registration, and FSSAI if food-grade APIs are involved. Export to regulated markets additionally requires WHO-GMP or US FDA approval.

How much does a small API manufacturing plant cost in India?

A small-scale API manufacturing plant in India typically requires an investment of ₹2–8 crore for a 1–5 MT/month capacity, covering reactors, distillation, QC lab, and effluent treatment. Regulatory compliance costs and working capital add to this. For regulated-market export readiness, budget an additional ₹2–5 crore for quality systems and validation.

What government schemes are available for API manufacturers?

Key schemes include: the PLI Scheme for Bulk Drugs (₹6,940 crore outlay, 10–20% incentive on incremental sales); the Bulk Drug Parks Promotion Scheme (ready plug-and-play infrastructure); CGTMSE collateral-free credit guarantee (up to ₹2 crore); CLCSS capital subsidy (15%); and state-level industrial policies in Telangana, Andhra Pradesh, Gujarat, and Himachal Pradesh.

Which states offer the best facilities for API manufacturing in India?

Telangana (Hyderabad pharma cluster), Andhra Pradesh (Visakhapatnam, Kakinada), Gujarat (Ahmedabad, Ankleshwar), Himachal Pradesh (Baddi), and Maharashtra (Pune, Nashik) are the leading states for pharmaceutical manufacturing facilities. Himachal Pradesh and Uttarakhand still offer legacy tax exemptions for new units in notified areas.

Can a small business enter the API sector, or is it only for large companies?

Small businesses can enter the API manufacturing business by focusing on niche APIs, synthesis intermediates, or toll manufacturing for larger pharma companies. The Bulk Drug Parks provide infrastructure without the capital requirement of a standalone facility. Many large API producers outsource intermediates production to smaller, specialised units.

What is the export potential for Indian API manufacturers?

India's API export potential is significant and growing. The country exported pharmaceutical products worth ~USD 27.8 billion in 2023–24, with bulk drugs forming a major share. The US, EU, Africa, and Latin America are primary markets. China+1 procurement trends and US FDA-approved Indian facilities provide structural advantages for export-oriented API producers.

Which APIs have the highest demand in India?

High-demand APIs in India include paracetamol, metformin, atorvastatin, amlodipine, omeprazole, azithromycin, and hydroxychloroquine for domestic consumption. For exports, antibiotics (cephalosporins, penicillin derivatives), anti-retrovirals, and anti-malarials are the largest categories. Oncology APIs and biosimilar ingredients are the fastest-growing segments.

How long does it take to get regulatory approval for an API plant?

State Drug Controller approval for domestic-market API manufacturing typically takes 6–12 months from application to licence. WHO-GMP certification adds 12–18 months. US FDA approval (required for exporting to the US market) involves a formal inspection and can take 18–36 months from plant readiness. Regulatory timeline is one of the most significant factors in project planning.

What raw materials are needed for API manufacturing?

Raw materials for bulk API production include key starting materials (KSMs), intermediates, reagents, solvents (acetone, methanol, ethyl acetate), and catalysts. Many KSMs are currently imported from China — the PLI scheme specifically targets domestic production of 41 such materials. Securing dual-source raw material supply is a critical risk management strategy for any API plant.

The Bottom Line

India's API manufacturing sector is at an inflection point. Decades of chemistry expertise, a large pool of pharmaceutical engineers, competitive manufacturing costs, and aggressive government support are converging with a global structural shift in pharmaceutical supply chains. The opportunity is real, and the policy environment is more supportive than at any previous time.

For entrepreneurs willing to navigate the regulatory complexity, the rewards — in domestic market share, export revenues, and long-term value creation — are substantial. Product selection is the critical strategic decision: commodity APIs require scale and cost discipline; specialty and complex APIs require technical depth and regulatory investment but deliver superior margins. Choose the segment that matches your capital, expertise, and risk appetite, and this is among the most durable industrial business ideas available in India today.

References

1. Pharmexcil (Pharmaceuticals Export Promotion Council of India) — India API and bulk drug export statistics, 2023–24

2. Ministry of Chemicals and Fertilizers, Government of India — PLI Scheme for Bulk Drugs, scheme guidelines and outlay data

3. Department for Promotion of Industry and Internal Trade (DPIIT) — Pharmaceutical sector investment and import substitution data

4. Ministry of Health & Family Welfare, Government of India — Licensed pharmaceutical manufacturing units in India

5. Confederation of Indian Industry (CII) — Indian pharmaceutical industry competitiveness report

6. Indian Pharmaceutical Alliance (IPA) — API sector capacity and regulatory standing overview